Evidence map›Paper›PMID 40751808›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN).

Thomas Büttner, Milka Marinova, Florian C Gaertner, Barbara Kreppel, Leander Fritsche, Christian Immanuel, Gerd Geraths, Stefan Kürpig, Jim Küppers, Ingo G H Schmidt-Wolf and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thomas Büttner *Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Milka Marinova *Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Milka.Marinova@ukbonn.de.ORCID 0000-0002-1856-5005
Florian C GaertnerDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Barbara KreppelDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Leander FritscheDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Christian ImmanuelDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Gerd GerathsDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Stefan KürpigDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Jim KüppersDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Ingo G H Schmidt-WolfDepartment of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Markus EsslerDepartment of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Manuel RitterDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Philipp KrausewitzDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose[

methodsWe retrospectively evaluated data from 386 mCRPC patients who had received [

resultsThe BRS served as an independent predictor of OS in multivariable analysis. The estimated median OS was 17.6, 10.9, 6.6, and 2.7 months for patients with scores of 0, 1, 2 and 3, respectively (Log-Rank P < 0.001). The tAUC values for predicting 1-year and 2-year OS were 71.6% and 74.4%, respectively. The CRP-enhanced score further improved prognostic accuracy, achieving tAUCs of 75.7% for 1-year OS and 78.1% for 2-year OS.

conclusionThe Bellmunt Risk Score effectively stratifies mCRPC patients undergoing [

Indexed as

DipeptidesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAntigens, SurfaceHumansLutetiumMaleMiddle AgedNeoplasm MetastasisPrognosisProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsAntigens, SurfaceDipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsBellmunt Risk ScoreLutetiummCRPCPredictionPSMASurvival

Identifiers

PMID40751808
PMCPMC12830477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.